Myeloma Flashcards
Role of CBP/P300 in Cancer
CBP (CREB-binding protein) and P300 are acetyltransferases, enzymes that add acetyl groups to proteins.
They play a key role in gene regulation, including genes that help cancer cells grow and survive.
In multiple myeloma, CBP/P300 contribute to therapy resistance by affecting gene expression and interacting with macrophages.
Multiple Myeloma and Therapy Resistance
Multiple myeloma (MM) is a type of blood cancer that affects plasma cells in the bone marrow.
Standard treatments (e.g., chemotherapy, immunotherapy) work for a while, but therapy resistance often develops.
One major reason for resistance is macrophages—immune cells in the tumor environment that can protect cancer cells from treatment.
How This Overcomes Macrophage-Driven Resistance
Macrophages in the tumor microenvironment support myeloma growth and shield it from therapy.
CBP/P300 help regulate macrophage activity in a way that makes them more protective of cancer cells.
Degrading CBP/P300 may alter macrophage function, making them less supportive of myeloma cells.
This could restore treatment sensitivity, making therapies like chemotherapy and immunotherapy more effective.
